A thousand points of light or just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging

Cancer Investigation

Volumn 17, Issue 5, 1999, Pages 322-334

  Moffat Jr , Frederick L ^a   Gulec, Seza A ^a   Serafini, Aldo N ^a   Sfakianakis, George N ^a   Pop, Raoul ^b   Robinson, David S ^c   Franceschi, Dido ^c   Boggs, Jodeen ^c   Livingstone, Alan S ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MIDDLEBURY COLLEGE   (United States)

^c Surgical Oncology ^*

Author keywords

[No Author keywords available]

Indexed keywords

INDIUM 111; MONOCLONAL ANTIBODY; RADIOISOTOPE; TECHNETIUM 99M;

ANTIBODY LABELING; CANCER RECURRENCE; CANCER SCINTISCANNING; CANCER SURGERY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DRUG SAFETY; IMMUNOGENICITY; IMMUNOSCINTIGRAPHY; INTERMETHOD COMPARISON; LABELING INDEX; LIVER METASTASIS; MEDICAL DECISION MAKING; OCCULT CANCER; PRIORITY JOURNAL; REVIEW;

EID: 0344142493     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909909032874     Document Type: Review

References (61)

1. Goldenberg DM, DeLand F, Kim E, et al: Use of radiolabeled antibodies to carcinoembryonic antigen in the detection and localization of diverse cancers by external photoscanning. N Engl J Med 298:1384-1388, 1978.
2. Swayne LC, Goldenberg DM, Diehl WL, et al: SPECT anti-CEA monoclonal antibody detection of occult colorectal carcinoma metastases. Clin Nucl Med 16:849-852, 1991.
3. 123I-labeled Fab′ or F(ab′)2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 77: 301-311, 1986.
4. Beatty JD, Hyams DM, Morton BA, et al: Impact of radiolabeled antibody imaging on management of colorectal cancer. Am J Surg 157:13-19, 1989.
5. Winzelberg GG, Grossman SJ, Rizk S, et al: Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Cancer 69:1656-1663, 1992.
6. Serafini AN, Vargas-Cuba RD, Benedetto P, et al: Clinical experience in utilizing radiolabeled monoclonal antibodies. Antib Immunoconj Radiopharm 4:77-83, 1991.
7. 99mTc-IMMU-4 monoclonal antibody scan in colorectal cancer. A prospective study. Arch Surg 127:1321-1324, 1992.
8. Moffat FL, Vargas-Cuba RD, Serafini AN, et al: Radioimmunodetection of colorectal carcinoma using technetium-99m-labeled Fab′ fragments of the IMMU-4 anti-carcinoembryonic antigen monoclonal antibody. Cancer 73:836-845, 1994.
9. Corbisiero RM, Yamauchi DM, Williams LE, et al: Comparison of immunoscintigraphy and computerized tomography in identifying colorectal cancer: individual lesion analysis. Cancer Res 51: 5704-5711, 1991.
10. Doerr RJ, Abdel-Nabi H, Krag DN, et al: Radiolabeled antibody imaging in the management of colorectal cancer. Ann Surg 214: 118-124, 1991.
11. Collier BD, Abdel-Nabi H, Doerr RJ, et al: Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 185:179-186, 1992.
12. 99mTc. Cancer Res (Suppl) 50:909-921, 1990.
13. Serafini AN, Goldenberg DM, Higginbotham-Ford EA, et al: A multicenter trial of cancer imaging with fragments of CEA monoclonal antibodies. J Nucl Med 30:748, 1989.
14. Goldenberg DM, Wlodkowski TJ, Sharkey RM, et al: Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. J Nucl Med 34:61-70, 1993.
15. Blend MJ, Ronan SG, Salk DJ, et al: Role of technetium 99m-labeled monoclonal antibody in the management of melanoma patients. J Clin Oncol 10:1330-1337, 1992.
16. 99mTc-labeled Fab′ fragment reactive with a high molecular weight melanoma antigen. Cancer Res 50(Suppl): 904s-908s, 1990.
17. Abdel-Nabi H, Wright GL, Gulfo JV, et al: Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol 10:45-54, 1992.
18. Granowska M, Mather SJ, Jobling T, et al: Radiolabeled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumors. Int J Biol Markers 5:89-96, 1990.
19. 111In-CYT-103 immunoscintigraphy in ovarian cancer. Gynecol Oncol 48:285-292, 1993.
20. 2 in the preoperative detection of clinical and subclinical lymph node metastases in breast cancer patients. Int J Cancer 3(Suppl):89-95, 1988.
21. Tjandra JJ, Sacks NPM, Thompson CH, et al: The detection of axillary lymph node metastases from breast cancer by radiolabeled monoclonal antibodies: a prospective study. Br J Cancer 59: 296-302, 1989.
22. Abdel-Nabi H, Schwartz AN, Wechter DG, et al: Scintigraphic detection of gastric and pancreatic carcinomas with In-111 ZCE 025 monoclonal antibody. World J Surg 15:122-127, 1991.
23. Haseman MK, Brown DW, Keeling CA, et al: Radioimmunodetection of occult carcinoembryonic antigen-producing cancer. J Nucl Med 33:1750-1757, 1992.
24. Moffat FL, Pinsky CM, Hammetshaimb L, et al: Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal Phase III trial. J Clin Oncol 14:2295-2305, 1996.
25. Serafini AN, Vargas-Cuba RD, Moffat FL, et al: Radioimmunoscintigraphy of colorectal cancer with Tc-99m-lgG3 whole human monoclonal antibody 88BV59. J Nucl Med 34:214P, 1993.
26. Gulec SA, Serafini AN, Moffat FL, et al: Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled totally human monoclonal antibody 88BV59H21-2. Cancer Res 55(Suppl):5774s-5776s, 1995.
27. Abdel-Nabi H, Doerr RJ, Chan H-W, et al: In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: safety, sensitivity and preliminary clinical results. Radiology 175: 163-171, 1990.
28. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50:814s-819s, 1990.
29. Nabi HA, Doerr RJ: Radiolabeled monoclonal antibody imaging (immunoscintigraphy) of colorectal cancers: current status and future perspectives. Am J Surg 163:448-456, 1992.
30. 111In-CYT-103; Oncoscint CR103) in patients with colorectal carcinoma. In: Diagnosis of Colorectal and Ovarian Carcinoma. Application of Immunoscintigraphic Technology, edited by RT Maguire, D Van Nostrand, New York, Marcel Dekker, 1992, pp. 73-88.
31. 2 fragment of an anti-CEA monoclonal antibody. Radiology 174:147-151, 1990.
32. Serafini AN, Vargas-Cuba RD, Benedetto P, et al: Tc-99m-Fab′ fragment of anti-CEA monoclonal antibody for the radioimmunodetection of colorectal adenocarcinoma. Antibod Immunoconj Radiopharm 4:561-568, 1991.
33. Patt YZ, Lamki LM, Shanken J, et al: Imaging with indium 111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol 8:1246-1254, 1990.
34. Patt YZ, Podoloff DA, Curley S, et al: Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. J Clin Oncol 12:489-495, 1994.
35. Hughes KS, Pinsky CM, Petrelli NJ, et al: Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. Ann Surg 226:621-631, 1997.
36. Gulec SA, Moffat FL, Carroll, RG: The expanding clinical role of intraoperative gamma probes. Nucl Med Ann, Philadelphia, Lippincott-Raven, 1997, pp. 209-237.
37. Losman MJ, DeJager RL, Monestier M, et al: Human immune response to anti-carcinoembryonic antigen murine monoclonal antibodies. Cancer Res 50(Suppl):1055s-1058s, 1990.
38. Reynolds JC, Del Vecchio S, Sakahara H, et al: Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Nucl Med Biol Int J Radiat Appl Instrum Part B 16:121-125, 1989.
39. Carrasquillo JA, Sugarbaker P, Colcher D, et al: Radioimmunoscintigraphy of colon cancer with iodine-131 labeled B72.3 monoclonal antibody. J Nucl Med 29:1022-1030, 1988.
40. Blottiére HM, Douillard JY, Koprowski H, et al: Immunoglobulin class and immunoglobulin G subclass analysis of human anti-mouse antibody response during monoclonal antibody treatment of cancer patients. Cancer Res 50(Suppl): 1051s-1054s, 1990.
41. Morton BA, O'Connor-Tressel M, Beatty BG, et al: Artifactual CEA elevation due to human anti-mouse antibodies. Arch Surg 123:1242-1246, 1988.
42. Hansen HJ, LaFontaine G, Newman ES, et al: Solving the problem of antibody interference in commercial "sandwich"-type immunoassays of carcinoembryonic antigen. Clin Chem 35:146-151, 1989.
43. Schroff RW, Foon KA, Beatty SM, et al: Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45:879-885, 1985.
44. Courtenay-Luck NS, Epenetos AA, Moore R, et al: Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 46:6489-6493, 1986.
45. Moffat FL, Vargas-Cuba RD, Serafini AN, et al: Preoperative scintigraphy and operative probe scintimetry of colorectal carcinoma using technetium-99m-88BV59. J Nucl Med 36:738-745, 1995.
46. Milenic DE, Yokota T, Filiputa DR, et al: Construction, binding properties, metabolism and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51:6363-6371, 1991.
47. Yokota T, Milenic DE, Whitlow M, et al: Microautographic analysis of normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 53:3776-3778, 1993.
48. Yokota T, Milenic DE, Whitlow M, et al: Rapid penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402-3408, 1992.
49. Nieroda CA, Milenic DE, Carrasquilla JA, et al: Improved tumor radioimmunodetection using a single-chain Fv and gamma-interferon: potential clinical applications for radioimmunoguided surgery and gamma-scanning. Cancer Res 55:2858-2865, 1995.
50. Begent RHJ, Verhaar MJ, Chester KA, et al: Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2:979-984, 1996.
51. Chester KA, Begent RHJ, Robson L, et al: Phage libraries for generation of clinically useful antibodies. Lancet 343:455-456, 1994.
52. 131I-CC49) when given in combination with gamma-interferon. Cancer Res 53:600-608, 1993.
53. Hnatowich DJ, Virzi F, Rusckowski M: Investigations of avidin and biotin for imaging applications. J Nucl Med 28:1294-1302, 1987.
54. Goodwin DA, Meares CF, McTigue M, et al: Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J Nucl Med 33:2006-2013, 1992.
55. Goodwin DA. New methods for localizing infection: a role for avidin-biotin? J Nucl Med 33:1816-1818, 1992.
56. Paganelli G, Magnani P, Zito F, et al: Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 51:5960-5966, 1991.
57. Goodwin DA, Meares CF, McCall MJ, et al: Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 29:226-234, 1988.
58. Peltier P, Curtet C, Chatal J-F, et al: Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 34:1267-1273, 1993.
59. Somasundaram C, Matzku S, Schuhmacher J, et al: Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy. Cancer Immunol Immunother 36:337-345, 1993.
60. Sivolapenko GB, Douli V, Peclasides D, et al: Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody. Lancet 346:1662-1666, 1995.
61. Modlin IM, Cornelius E, Lawton GP: Use of an isotopic somatostatin receptor probe to image gut endocrine tumors. Arch Surg 130:367-374, 1995.